POC(Point of Care) 유전자 검사 시장 : 예측(2026-2031년)

Point-Of-Care Genetic Testing Market, with a 5.55% CAGR, is expected to grow to USD 2.678 billion in 2031 from USD 1.937 billion in 2025.

The point-of-care genetic testing (POC GT) market is a transformative and rapidly expanding segment within the diagnostics and precision medicine landscape. It is defined by the execution of genetic analyses outside of centralized laboratory settings, providing actionable results at or near the patient location within a clinically relevant timeframe. This decentralization, enabled by portable and integrated platforms, is fundamentally altering the paradigm of genetic diagnostics by dramatically reducing turnaround times, simplifying testing workflows, and integrating genetic data directly into immediate clinical decision-making.

Core Market Drivers and Clinical Imperatives

The primary catalyst for market growth is the accelerating transition toward personalized and precision medicine. As therapeutic strategies become increasingly tailored to an individual's genetic profile, the need for rapid, accessible genotyping has become paramount. POC genetic testing fulfills this need by enabling clinicians to make data-driven decisions on drug selection, dosing, and therapy stratification at the point of clinical interaction. This capability is critical in fields like oncology, pharmacogenomics, and infectious disease, where timely genetic information directly impacts treatment efficacy and patient outcomes.

A concurrent driver is the expanding technical capabilities of point-of-care platforms themselves. Advances in microfluidics, biosensors, and molecular diagnostics have converged to create sophisticated, yet user-friendly, systems capable of performing complex genetic analyses-such as PCR, isothermal amplification, and targeted sequencing-in decentralized settings. These systems integrate sample preparation, amplification, and detection into automated, cartridge-based workflows, minimizing hands-on time and technical expertise required. This technological evolution is transforming POC GT from a concept for simple tests into a viable modality for a broadening range of clinically significant genetic markers.

Furthermore, growing clinical and patient awareness of the role of genetics in health and disease is creating sustained demand. Increased public understanding of hereditary conditions, coupled with physician education on genomic medicine, is driving proactive testing for risk assessment, early diagnosis, and family planning. The inherent advantages of POC testing-convenience, speed, and reduced need for patient follow-up-align perfectly with this trend, facilitating higher testing uptake and integration into routine care pathways, particularly in primary and acute care settings.

Strategic Advantages and Value Proposition

The definitive value proposition of POC genetic testing lies in its capacity for rapid results and timely decision-making. By eliminating the logistical delays associated with sample transport and batch processing in core labs, it compresses the diagnostic timeline from days or weeks to minutes or hours. This acceleration enables immediate clinical actions, such as initiating targeted therapy, adjusting medication, or implementing infection control measures, which can significantly improve patient management, streamline hospital workflows, and reduce overall healthcare costs. The ability to obtain genetic information during a single patient visit also enhances care continuity and patient satisfaction.

Geographic Market Dynamics

North America is established as the leading regional market, a position sustained by a synergistic combination of advanced healthcare infrastructure, high adoption of precision medicine, favorable reimbursement frameworks, and significant investment in diagnostic innovation. The presence of major platform developers and a robust biotech sector further consolidates this leadership. However, the market is experiencing global expansion. Regions such as Europe and Asia-Pacific are witnessing accelerated growth driven by increasing healthcare modernization, rising prevalence of genetic disorders, and growing investment in decentralized care models, indicating a broadening geographic footprint for POC GT solutions.

Competitive Landscape and Platform Evolution

The competitive environment is characterized by established diagnostic corporations and specialized molecular companies. Leaders compete on the basis of test menu breadth, analytical performance, ease of use, speed, and connectivity within digital health ecosystems. The market features fully integrated, cartridge-based systems that dominate the infectious disease segment and are increasingly penetrating oncology and pharmacogenomic applications. Strategic focus is on expanding test panels to cover more genetic targets, improving multiplexing capabilities, and ensuring platforms can operate reliably in varied resource settings. Success depends on demonstrating clear clinical utility, cost-effectiveness, and seamless integration into diverse clinical workflows.

Challenges and Future Trajectory

Market growth faces challenges, including the need for stringent regulatory validation of decentralized tests, ensuring consistent quality control outside the lab environment, and navigating reimbursement policies for novel POC assays. The initial cost of platforms and cartridges can also be a barrier to widespread adoption in cost-sensitive settings.

Nevertheless, the long-term trajectory is unequivocally toward expansion and sophistication. Future growth will be driven by the continuous miniaturization of technology, the development of new biomarker panels for chronic disease and oncology, and the integration of artificial intelligence for result interpretation. The convergence of POC genetic testing with telehealth and digital health records will further solidify its role in creating a continuous, data-driven loop between diagnosis and treatment.

In conclusion, the point-of-care genetic testing market represents a pivotal shift toward immediate, actionable genomics. Its evolution is inextricably linked to the advancement of precision medicine and the decentralization of diagnostic capabilities. For industry experts, the strategic imperative lies in developing robust, CLIA-waived platforms with expanding clinical menus, generating robust health-economic evidence, and navigating the pathway to regulatory approval and reimbursement. The future points toward POC genetic testing becoming an embedded tool across the care continuum, fundamentally enhancing the speed and personalization of medical intervention.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Point-of-Care Genetic Testing Market Segmentation

• By Type
• Polymerase Chain Reaction (PCR)
• Isothermal Amplification
• Others
• By Application
• Infectious Disease
• Cancer Screening
• Personalized Medicine
• Others
• By End-User
• Hospitals
• Specialized Clinics
• Others
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. POINT-OF-CARE GENETIC TESTING MARKET BY TYPE

• 5.1. Introduction
• 5.2. Polymerase Chain Reaction (PCR)
• 5.3. Isothermal Amplification
• 5.4. Others

6. POINT-OF-CARE GENETIC TESTING MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Infectious Disease
• 6.3. Cancer Screening
• 6.4. Personalized Medicine
• 6.5. Others

7. POINT-OF-CARE GENETIC TESTING MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Specialized Clinics
• 7.4. Others

8. POINT-OF-CARE GENETIC TESTING MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Abbott
• 10.2. F. Hoffmann-La Roche Ltd
• 10.3. Thermo Fisher Scientific Inc.
• 10.4. Qiagen N.V.
• 10.5. Bio-Rad Laboratories, Inc.
• 10.6. Becton Dickinson
• 10.7. Danaher Corporation
• 10.8. bioMerieux
• 10.9. Siemens Healthineers AG
• 10.10. OraSure Technologies Inc

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations